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Abstract
Aldosterone mediates many of the physiological and 
pathophysiological/cardio-toxic effects of angiotensin 
II (AngII). Its synthesis and secretion from the zona 
glomerulosa cells of the adrenal cortex, elevated in 
chronic heart failure (HF), is induced by AngII type 1 
receptors (AT1Rs). The AT1R is a G protein-coupled 
receptor, mainly coupling to Gq/11 proteins. However, 
it can also signal through β-arrestin-1 (βarr1) or -2 
(βarr2), both of which mediate G protein-independent 
signaling. Over the past decade, a second, Gq/11 protein-
independent but βarr1-dependent signaling pathway 
emanating from the adrenocortical AT1R and leading 
to aldosterone production has become appreciated. 
Thus, it became apparent that AT1R antagonists that 
block both pathways equally well are warranted for 
fully effective aldosterone suppression in HF. This 
spurred the comparison of all of the currently marketed 
angiotensin receptor blockers (ARBs, AT1R antagonists 
or sartans) at blocking activation of the two signaling 
modes (G protein-, and βarr1-dependent) at the AngII-
activated AT1R and hence, at suppression of aldosterone 
in vitro  and in vivo . Although all agents are very potent 
inhibitors of G protein activation at the AT1R, cande-
sartan and valsartan were uncovered to be the most 
potent ARBs at blocking βarr activation by AngII and at 
suppressing aldosterone in vitro  and in vivo  in post-myo-
cardial infarction HF animals. In contrast, irbesartan and 
losartan are virtually G protein-“biased” blockers at the 
human AT1R, with very low efficacy for βarr inhibition 
and aldosterone suppression. Therefore, candesartan 
and valsartan (and other, structurally similar compounds) 
may be the most preferred ARB agents for HF pharma-
cotherapy, as well as for treatment of other conditions 
characterized by elevated aldosterone. 
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Core tip: The angiotensin II type 1 receptor (AT1R) 
endogenously expressed in adrenocortical cells was 
known for decades to induce aldosterone production 
via  a well-defined Gq protein-mediated signaling 
pathway. Over the past decade, a number of studies 
have elucidated another, β-arrestin-1 (βarr1)-dependent 
signaling cascade, which proceeds in parallel to, and 
independently of the Gq-mediated one, and also results 
in aldosterone synthesis and secretion from the adrenal 
cortex. Importantly, although all of the Food and Drug 
Administration-approved angiotensin receptor blocker 
(ARB) drugs (AT1R antagonists) are very effective 
at blocking the Gq-mediated pathway, as expected, 
since they were designed to do so (i.e. , to block the 
G protein signaling of the AT1R), they seem to display 
varying efficacies at blocking this new, βarr1-dependent 
pathway, which translates into significant variation at 
aldosterone suppression efficacies. In that context, 
candesartan and valsartan appear the most effective 
agents at blocking also the βarr1 pathway emanating 
from the adrenocortical AT1R, and thus, these two 
agents may be the best aldosterone suppressors within 
the ARB drug class.
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INTRODUCTION
Aldosterone is a mineralocorticoid hormone with 
several cardio-toxic actions, whose plasma levels are 
extremely high in chronic heart failure (HF) negatively 
affecting progression of the disease[1]. Amongst its main 
actions on the failing myocardium is overall promotion 
of adverse remodeling via maladaptive hypertrophy, 
chamber dilatation, collagen deposition and fibrosis, 
increased inflammation and reactive oxygen species 
production, etc. The net result of all of these effects is 
acceleration of cardiac functional decline[2-4]. The main 
source of circulating aldosterone is the adrenocortical zona 
glomerulosa (AZG) cells, which synthesize and secrete 
it in response to high serum K+ levels (hyperkalemia), 
since its main action on the kidneys is K+ excretion (along 
with Na+ and water reabsorption)[5]. Another powerful 
physiological stimulus for aldosterone secretion from 
AZG cells is the octapeptide hormone angiotensin II 
(AngII), which activates its type 1 receptors (AT1Rs), 
endogenously expressed in AZG cells[5,6]. 
The AT1R is a 7-transmembrane-spanning or G pro-
tein-coupled receptor (GPCR); upon agonist activation, 
it couples primarily to the Gq/11 family of G proteins[6]. 
Nowadays however, it is known to signal also through 
other types of G proteins, like Gi/o and Gs, as well as 
through G protein-independent pathways mediated 
by the universal GPCR adapter proteins β-arrestin-1 
(βarr1) and βarr2 (also known as arrestin-2 and -3, 
respectively)[7-9]. The βarrs bind agonist-activated and 
GPCR-kinase (GRK)-phosphorylated GPCRs to uncouple 
them from G proteins (receptor desensitization) and to 
target them to clathrin-coated vesicles for internalization 
(receptor endocytosis). At the same time, they initiate 
their own, “second wave” of signal transduction inde-
pendently of G proteins[10-13].
ANGII-DEPENDENT ALDOSTERONE 
PRODUCTION: THE SUM OF TWO 
SIGNALING MODALITIES
The Gq/11 protein-dependent signaling pathway elicited 
by the AngII-activated AT1R that culminates in aldo-
sterone synthesis and secretion in AZG cells has been 
well characterized (Figure 1)[14]. More specifically, 
diacylglycerol (DAG) and inositol trisphosphate (IP3), 
the two second messengers produced by this pathway, 
ultimately lead to: (1) aldosterone secretion, via 
elevated intracellular free Ca2+ concentration, which 
directly stimulates exocytosis and hormonal (in the 
context of AZG cells, aldosterone) secretion; and 
(2) aldosterone synthesis, via extracellular signal-
regulated kinase (ERK) MAPK activation, which, in 
turn, stimulate aldosterone biosynthesis in AZG cells by 
transcriptionally upregulating the StAR (steroidogenic 
acute regulatory) protein[14]. This protein mediates the 
mitochondrial uptake of the precursor of all adrenal 
steroids cholesterol and is the rate-limiting enzyme of 
aldosterone biosynthesis in AZG cells[14]. 
In the chronic HF setting, adrenal GRK2 is up-
regulated and, along with βarr1, hyperphosphorylates 
and severely desensitizes the sympatho-inhibitory 
α2-adrenergic receptors (ARs) of chromaffin cells in 
the adrenal medulla[15-21]. The result of this is chronic 
elevation of adrenal catecholamine secretion, which 
significantly contributes to the heightened sympathetic 
nervous system outflow and increased norepinephrine 
and epinephrine levels that further damage the failing 
heart[22-26]. Since aldosterone is also increased in HF 
and its production is stimulated by the AT1Rs of the 
adrenal cortex[1], which are also GRK2 and βarr1 
substrates, it was theorized that the upregulated (in 
HF) adrenal GRK2 could lead to excessive interaction 
of βarr1 also with the AT1R in the adrenal cortex, 
thereby modulating aldosterone secretion in the chronic 
HF setting, as well. Indeed, this was found to be the 
case[27]. Via a combination of in vitro experiments in the 
human AZG cell line H295R and in vivo experiments 
in experimental rats developing HF following an acute, 
surgically induced myocardial infarction (MI), we were 
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able to show that adrenal βarr1 actually promotes 
AngII-dependent aldosterone synthesis and secretion by 
also mediating AT1R signaling to ERK-dependent StAR 
upregulation independently of G proteins (Figure 1)[27,28]. 
This finding was somewhat surprising, given that βarr1 
would normally be expected to reduce AngII-dependent 
aldosterone production thanks to desensitizing the 
AT1R (terminating its G protein-dependent signaling, 
see above). Nevertheless, it was discovered that, 
after abolishing the Gq-dependent signaling by the 
AT1R in AZG cells, AT1R-bound βarr1 initiated its own 
signaling to aldosterone synthesis by recruiting a DAG-
kinase to the activated receptor[29], which converted 
the second messenger lipid DAG to phosphatidic acid 
(PA)[27]. PA can directly activate the small (monomeric) 
G protein Ras at the plasma membrane, which then 
initiates the cascade that results in ERK phosphorylation 
and activation[30]. Thus, AT1R-activated βarr1 elicits 
a “second (delayed) wave” of signaling leading to 
sustained ERK activation in AZG cells in its own right 
(i.e., independently of G proteins), which, as discussed 
above, promotes aldosterone production via StAR 
upregulation[27]. Importantly, since StAR regulates 
synthesis not only of aldosterone but of all adrenal 
steroids throughout the three anatomical zones of the 
adrenal cortex[14], adrenal βarr1 may also affect the 
synthesis of glucocorticoids and of androgens in the 
adrenal cortex.
Notably, adrenal βarr1 may not only stimulate the 
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AT1R-dependent aldosterone synthesis via its “second 
wave” of signaling to ERK-dependent StAR upregulation 
but also facilitate the acute AT1R-dependent aldosterone 
secretion at the plasma membrane of AZG cells and 
in parallel to the G protein-mediated signaling by the 
receptor (Figure 1). Recent evidence in transfected 
heterologous systems suggests such a role in the “first 
wave” of GPCR signaling for the βarrs[31,32] and a very 
intriguing study, done specifically in the adrenal medulla, 
suggested an acute stimulation of catecholamine 
secretion and of Ca2+-dependent exocytosis by AT1R-
activated βarr1 (but interestingly not by βarr2) in 
adrenal chromaffin cells, thanks to its direct interaction 
with the plasma membrane Ca2+ channel short transient 
receptor potential channel-3 (TRPC3)[33]. Thus, it is quite 
plausible that AT1R-bound βarr1 can directly stimulate 
TRPC3-dependent Ca2+ currents and hence, exocytosis, 
also in AZG cells, thereby acutely stimulating AngII-
dependent aldosterone secretion within seconds of 
agonist binding (and in parallel to the Gq-mediated 
signaling by the AT1R). This interesting possibility of 
another signaling mechanism by which βarr1 can induce 
aldosterone production in AZG cells is definitely worthy 
of investigation in future studies.
Most importantly, adrenal βarr1-dependent aldo-
sterone production has been documented to occur also 
in vivo, both under physiological (in normal, healthy 
animals) and pathophysiological (in the post-MI HF 
setting) conditions[27,28]. Specifically, adrenal-targeted 
AZG cellAT1R
G prtβarr1
Aldosterone
N
N
HO O
N N
NN
CH3
AngII
Figure 1  Angiotensin II type 1 receptor and aldosterone production. Schematic representation of the parallel G prt- and βarr1-mediated, AngII-bound AT1R 
signaling cascades that converge on mitochondrial aldosterone synthesis in adrenocortical zona glomerulosa (AZG) cells. The structure of the proposed AT1R 
antagonist (2-pentyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid)[40], discussed in the text, capable of suppressing 
both pathways equally well, is also shown (upper left corner). See text for details. G prt: Gq protein; βarr1: β-arrestin1; AngII: Angiotensin II; AT1R: AngII type 1 
receptor. 
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currently Food and Drug Administration (FDA)-approved 
ARB drugs, it was found that, although all ARBs (including 
losartan) are potent inhibitors of G protein activation by 
the AT1R, their potencies at preventing βarr1 activation 
by the human AT1R in vitro varied enormously[40]. 
Specifically, candesartan and valsartan appeared the 
most potent blockers of βarr1 activation and the most 
efficacious aldosterone suppressors in vitro and in 
vivo[39,40]. At the opposite end of the spectrum and in 
addition to losartan, was irbesartan, which was found 
to be a very weak βarr1 inhibitor and hence, a very 
ineffective aldosterone suppressor both in vitro and in 
vivo, despite its excellent G protein-blocking ability[39,40]. 
The rest of the class fell more or less in the middle of 
the βarr1 inhibition and AT1R-dependent aldosterone 
suppression scales, i.e., their potency values were lower 
than candesartan’s and valsartan’s but much higher 
than losartan’s and irbesartan’s[39,40]. Importantly, their 
effects on cardiac function of in post-MI HF animals in 
vivo were in complete concordance with their effects 
on circulating aldosterone levels; candesartan and 
valsartan induced significant improvements in cardiac 
function and remodeling post-MI, whereas irbesartan 
and losartan were not able to alter the course of 
progression of post-MI animals to full-blown HF[39]. 
IMPLICATIONS FOR HF 
PHARMACOTHERAPY
It is widely recognized nowadays that the members 
of the ARB drug class display significant variation in 
their pharmacological and clinical properties, which 
has significant repercussion for their use in HF pharma­
cotherapy[41]. In fact, certain agents have already been 
shown to afford larger improvements in morbidity and 
mortality of chronic HF than others[42-45]. Part of the 
reason for these differences among these agents that 
belong to the same pharmacological class and share 
the same mechanism of action (AT1R antagonism) 
may be differences in their efficacies at combating the 
hyperaldosteronism that accompanies and burdens 
chronic HF[1]. In other words, agents that suppress 
aldosterone effectively are bound to work better for HF 
therapy and, since adrenal βarr1 plays a pivotal role 
in regulation of this cardio-toxic hormone’s levels, the 
ARBs that are most effective at blocking the AT1R-βarr1 
interaction in the adrenal cortex would be expected to 
be preferred agents. In that vein, our aforementioned 
recent findings that candesartan and valsartan are the 
most efficacious βarr1 inhibitors at the AT1R, coupled 
with their excellent efficacy at lowering aldosterone 
in vitro and in vivo, point to these two ARBs as being 
the most preferable agents of their class to use in HF 
treatment (and in other hyperaldosteronic conditions, 
e.g., salt-sensitive hypertension). In contrast, irbesartan 
and losartan were found very weak βarr1-dependent 
aldosterone inhibitors, a finding that may have some 
bearing on the lack of therapeutic benefit of these two 
βarr1 overexpression increased aldosterone serum 
levels in vivo in normal rats[27], and caused severe 
hyperaldosteronism also in post-MI rats on top of the 
circulating aldosterone elevation normally occurring due 
to the MI injury[28]. Importantly, in the latter animals, 
adrenal-specific βarr1 blockade in vivo with a βarr1 
C-terminal fragment during post-MI HF progression 
helped stall the decline of cardiac function and even 
reversed several aspects/markers of adverse cardiac 
remodeling courtesy of normalization of circulating 
aldosterone levels[28]. What’s more, aldosterone levels 
remarkably show no increase in βarr1-knockout mice 
post-MI, which further highlights the importance of 
adrenal βarr1 in regulation of circulating aldosterone 
levels[34]. Together, these in vivo studies strongly suggest 
adrenal βarr1, in conjunction with GRK2, as an attractive 
therapeutic target for diseases associated with, and 
aggravated by hyperaldosteronism, such as post-MI 
HF[9,25]. Adding to its importance as a therapeutic target 
is also the fact that aldosterone can produce effects 
independently of its mineralocorticoid receptor (MR) 
(the so-called “non-genomic” actions of aldosterone)[4]. 
Obviously, these effects cannot be countered by 
MR antagonist drugs (e.g., eplerenone, finerenone, 
spironolactone) and thus, suppression of aldosterone 
production at its source, i.e., the adrenal cortex, via 
adrenal βarr1 blockade would be much more preferable 
from the therapeutic standpoint.
WHICH ARB DRUG WINS THE 
ALDOSTERONE SUPPRESSION 
“CONTEST”?
The realization that AngII-dependent aldosterone 
production from the adrenal cortex proceeds through 
two independent signaling modalities, i.e., Gq protein- 
and βarr1-dependent (Figure 1), signaled that complete 
blockade of both of these modalities is needed to attain 
full suppression of adrenal aldosterone production and 
effectively lower circulating aldosterone levels in HF 
and in other diseases. This, coupled with the fact that 
some AT1R antagonist drugs (angiotensin receptor 
blockers, ARBs, or sartans) appear ineffective at 
lowering aldosterone in HF, despite their full capacity 
to block AT1R-G protein coupling[35-38], prompted us 
to test the relative efficacy of the currently available 
ARBs at inhibiting the βarr1-dependent aldosterone 
production by the AT1R in an effort to identify the 
most effective agent(s). Indeed, the prototypic agent 
of this class, losartan, was found totally ineffective 
at preventing adrenal βarr1-dependent aldosterone 
production and combatting hyperaldosteronism post-MI 
due to very weak antagonism of βarr1 activation by the 
AT1R[28]. Interestingly however, the active metabolite of 
losartan EXP1374 was found quite effective at blocking 
AT1R-dependent aldosterone production and βarr1 
activation[39,40].
Upon subsequent head-to-head testing of all the 
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carboxyl acid group with a long aliphatic chain on the 
other end of the tetrazolo-biphenyl-methylene back-
bone, and we are currently testing both its potency at 
blocking βarr1 activation by the human AT1R and its 
efficacy at suppressing aldosterone secretion in vitro and 
in the post-MI HF setting in vivo. Our hope is that it will 
prove to be even more efficacious than candesartan and 
valsartan at suppressing aldosterone levels and thus, 
an even better drug for HF treatment than all currently 
available ARBs. Of course, the above mentioned ARB 
structure-activity relationship inferences have to be 
confirmed by crystal structure resolutions of the AT1R 
bound to βarrs. The first glimpse into the human AT1R 
crystal structure was recently provided and it was the 
first step towards that goal[50]. Unfortunately however, 
that crystal structure lacked the intracellular C-terminal 
tail of the receptor, which is exactly the AT1R region that 
interacts with βarrs [51]. 
CONCLUSION
A head-to-head comparison of the ARBs currently on 
the United States market identified candesartan and 
valsartan as the most potent βarr1 antagonists and 
the most efficacious aldosterone suppressors at the 
human AT1R. Conversely, irbesartan and losartan were 
found to be largely G protein-“biased” inhibitors, with 
minimal efficacy towards inhibition of AngII-dependent 
aldosterone production. Thus, from a therapeutic stand-
point, candesartan and valsartan may be the most 
preferable agents of this drug class, as they provide the 
biggest benefit for cardiac function and patient survival 
in post-MI HF and have the lowest propensity to cause 
the “aldosterone escape” adverse effect (failure to 
suppress aldosterone). Future studies on this class of 
drugs and on the effects of βarrs at the adrenal AT1R 
will help solidify these inferences and will also provide 
additional important information regarding AngII/AT1R 
pharmacology for clinicians and medicinal chemists alike. 
REFERENCES
1 Weber KT. Aldosterone in congestive heart failure. N Engl J 
Med 2001; 345: 1689­1697 [PMID: 11759649 DOI: 10.1056/
NEJMra000050]
2 Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 
2005; 186: 1­20 [PMID: 16002531 DOI: 10.1677/joe.1.06017]
3 Marney AM, Brown NJ. Aldosterone and end­organ damage. Clin 
Sci (Lond) 2007; 113: 267­278 [PMID: 17683282 DOI: 10.1042/
CS20070123]
4 Zhao W, Ahokas RA, Weber KT, Sun Y. ANG II­induced cardiac 
molecular and cellular events: role of aldosterone. Am J Physiol 
Heart Circ Physiol 2006; 291: H336­H343 [PMID: 16489102 DOI: 
10.1152/ajpheart.01307.2005]
5 Ganguly A, Davis JS. Role of calcium and other mediators in 
aldosterone secretion from the adrenal glomerulosa cells. Pharmacol 
Rev 1994; 46: 417­447 [PMID: 7899472]
6 de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International 
union of pharmacology. XXIII. The angiotensin II receptors. 
Pharmacol Rev 2000; 52: 415­472 [PMID: 10977869]
7 Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for beta­arrestins 
in cell signaling: not just for seven­transmembrane receptors. 
agents demonstrated in HF with preserved ejection 
fraction (HF-PEF) and on their therapeutic inferiority 
to candesartan in terms of HF mortality reduction[44,45]. 
Of course, future trials providing data on the serum 
aldosterone levels of the ARB-treated HF patients are 
needed to confirm such a link between adrenal βarr1-
dependent aldosterone suppression efficacy and clinical 
benefit for this important cardiovascular drug class. 
On the other hand, failure of these agents to sup-
press aldosterone, otherwise referred to as “aldosterone 
breakthrough” or “aldosterone escape”, is a clinically 
well-documented phenomenon[46-49] and the efficacy of 
each agent at inhibiting βarr1-dependent aldosterone 
production may be inversely proportional to the pro-
bability of the ARB to exhibit it. In other words, the more 
potent βarr1-dependent aldosterone suppressor an ARB 
is, the lower the likelihood is that the treated patient will 
suffer from “aldosterone breakthrough”. Thus, cande-
sartan and valsartan may be the safest ARB drugs to 
use in HF patients in terms of the risk of “aldosterone 
breakthrough”. However, large trials closely monitoring 
the circulating aldosterone levels of treated patients are 
again needed in order to confirm this hypothesis. 
IMPLICATIONS FOR AT1R BLOCKER 
MEDICINAL CHEMISTRY
The studies on the relative potencies/efficacies of the 
currently FDA-approved ARBs at inhibiting AT1R-βarr1 
interaction and βarr1-dependent aldosterone turnover 
provided some interesting medicinal chemistry and 
pharmacological insights, as well. Specifically, as far as 
the ARBs that are tetrazolo-biphenyl-methyl derivatives 
are concerned, which is a subgroup that includes 
losartan (and its metabolite EXP1374), irbesartan, 
candesartan, valsartan, and olmesartan, it was con-
cluded that a substitution both bulky and negatively 
charged attached to the one side of the methylene 
group of the biphenyl-methyl backbone (the other end 
has the tetrazolo-biphenyl group attached) is needed 
to confer good inhibitory potency of βarr1 at the AT1R 
and consequently, effectively suppress aldosterone[40]. 
Indeed, both candesartan and valsartan, as well as 
EXP1374, have spacious, long aliphatic chain-containing 
and anionic (carboxylic acid) groups attached to that 
end of the biphenyl-methyl backbone[40]. In contrast, 
both losartan and irbesartan possess neutrally charged 
(unionizable) groups (albeit also bulky) at that biphenyl-
methyl backbone end[40]. Finally, olmesartan, which 
also has an anionic (carboxylic acid) substitution but of 
intermediate bulkiness (i.e., less long aliphatic chain) 
compared to candesartan and valsartan on that side of 
its backbone, displays intermediate potency at inhibiting 
βarr1 activation and suppressing aldosterone[40]. 
Based on these observations, we have designed the 
compound 2-pentyl-1-({4-[2-(2H-1,2,3,4-tetrazol-
5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-
carboxylic acid (Figure 1)[40], which carries a bulky, 
Lymperopoulos A et al . ARBs and β-arrestin-dependent aldosterone suppression
205 March 26, 2017|Volume 9|Issue 3|WJC|www.wjgnet.com
system activity in heart failure. World J Cardiol 2015; 7: 539­543 
[PMID: 26413230 DOI: 10.4330/wjc.v7.i9.539]
26 Rengo G, Leosco D, Zincarelli C, Marchese M, Corbi G, Liccardo 
D, Filippelli A, Ferrara N, Lisanti MP, Koch WJ, Lymperopoulos 
A. Adrenal GRK2 lowering is an underlying mechanism for the 
beneficial sympathetic effects of exercise training in heart failure. 
Am J Physiol Heart Circ Physiol 2010; 298: H2032­H2038 [PMID: 
20304818 DOI: 10.1152/ajpheart.00702.2009]
27 Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, 
Koch WJ. An adrenal beta­arrestin 1­mediated signaling pathway 
underlies angiotensin II­induced aldosterone production in vitro and 
in vivo. Proc Natl Acad Sci USA 2009; 106: 5825­5830 [PMID: 
19289825 DOI: 10.1073/pnas.0811706106]
28 Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. 
Adrenal beta­arrestin 1 inhibition in vivo attenuates post­myocardial 
infarction progression to heart failure and adverse remodeling via 
reduction of circulating aldosterone levels. J Am Coll Cardiol 2011; 
57: 356­365 [PMID: 21232674 DOI: 10.1016/j.jacc.2010.08.635]
29 Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, 
Lefkowitz RJ. Targeting of diacylglycerol degradation to M1 
muscarinic receptors by beta­arrestins. Science 2007; 315: 663­666 
[PMID: 17272726 DOI: 10.1126/science.1134562]
30 Rizzo MA, Shome K, Watkins SC, Romero G. The recruitment 
of Raf­1 to membranes is mediated by direct interaction with 
phosphatidic acid and is independent of association with Ras. J Biol 
Chem 2000; 275: 23911­23918 [PMID: 10801816 DOI: 10.1074/jbc.
M001553200]
31 Eichel K, Jullié D, von Zastrow M. β-Arrestin drives MAP kinase 
signalling from clathrin­coated structures after GPCR dissociation. 
Nat Cell Biol 2016; 18: 303­310 [PMID: 26829388 DOI: 10.1038/
ncb3307]
32 Nuber S, Zabel U, Lorenz K, Nuber A, Milligan G, Tobin AB, 
Lohse MJ, Hoffmann C. β-Arrestin biosensors reveal a rapid, 
receptor­dependent activation/deactivation cycle. Nature 2016; 531: 
661­664 [PMID: 27007855 DOI: 10.1038/nature17198]
33 Liu CH, Gong Z, Liang ZL, Liu ZX, Yang F, Sun YJ, Ma ML, 
Wang YJ, Ji CR, Wang MJ, Lin A, Zheng WS, He DF, Qu CX, Liu 
CY, Cahill TJ, Kahsai AW, Yi F, Xiao KH, Xue T, Zhou Z, Yu X, 
Sun JP. Arrestin­biased GPCR agonism induces acute catecholamine 
secretion through TRPC3 coupling. Nat Commun 2017; 8: 14335 
[PMID: 28181498 DOI: 10.1038/ncomms14335]
34 Bathgate-Siryk A, Dabul S, Pandya K, Walklett K, Rengo G, 
Cannavo A, De Lucia C, Liccardo D, Gao E, Leosco D, Koch 
WJ, Lymperopoulos A. Negative impact of β-arrestin-1 on post-
myocardial infarction heart failure via cardiac and adrenal­dependent 
neurohormonal mechanisms. Hypertension 2014; 63: 404­412 [PMID: 
24218435 DOI: 10.1161/HYPERTENSIONAHA.113.02043]
35 Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret 
C, Leenhardt A, Safar ME, Delcayre C, Milliez P. Spironolactone 
improves carotid artery fibrosis and distensibility in rat post­
ischaemic heart failure. J Mol Cell Cardiol 2005; 39: 511­519 
[PMID: 15992819 DOI: 10.1016/j.yjmcc.2005.05.015]
36 Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by 
spironolactone in spontaneously hypertensive rats. Arterioscler 
Thromb Vasc Biol 1997; 17: 1152­1156 [PMID: 9194767 DOI: 
10.1161/01.ATV.17.6.1152]
37 Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani 
B. Evidence of a partial escape of renin­angiotensin­aldosterone 
blockade in patients with acute myocardial infarction treated 
with ACE inhibitors. J Clin Pharmacol 1993; 33: 40­45 [PMID: 
8429112 DOI: 10.1002/j.1552­4604.1993.tb03901.x]
38 Struthers AD. Aldosterone escape during ACE inhibitor therapy 
in chronic heart failure. Eur Heart J 1995; 16 Suppl N: 103­106 
[PMID: 8682054 DOI: 10.1093/eurheartj/16.suppl_N.103]
39 Lymperopoulos A, Sturchler E, Bathgate­Siryk A, Dabul S, Garcia 
D, Walklett K, Rengo G, McDonald P, Koch WJ. Different potencies 
of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-
dependent post­myocardial infarction hyperaldosteronism. J Am 
Coll Cardiol 2014; 64: 2805­2806 [PMID: 25541135 DOI: 10.1016/
j.jacc.2014.09.070]
Mol Cell 2006; 24: 643­652 [PMID: 17157248 DOI: 10.1016/
j.molcel.2006.11.007]
8 Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by 
beta­arrestins. Science 2005; 308: 512­517 [PMID: 15845844 DOI: 
10.1126/science.1109237]
9 Lymperopoulos A, Bathgate A. Arrestins in the cardiovascular 
system. Prog Mol Biol Transl Sci 2013; 118: 297­334 [PMID: 
23764059 DOI: 10.1016/B978­0­12­394440­5.00012­7]
10 Lymperopoulos A, Negussie S. βArrestins in cardiac G protein-
coupled receptor signaling and function: partners in crime or “good 
cop, bad cop”? Int J Mol Sci 2013; 14: 24726­24741 [PMID: 
24351844 DOI: 10.3390/ijms141224726]
11 Lymperopoulos A, Bathgate A. Pharmacogenomics of the 
heptahelical receptor regulators G­protein­coupled receptor kinases 
and arrestins: the known and the unknown. Pharmacogenomics 
2012; 13: 323­341 [PMID: 22304582 DOI: 10.2217/pgs.11.178]
12 Capote LA, Mendez Perez R, Lymperopoulos A. GPCR signaling 
and cardiac function. Eur J Pharmacol 2015; 763: 143­148 [PMID: 
25981298 DOI: 10.1016/j.ejphar.2015.05.019]
13 Luttrell LM, Gesty­Palmer D. Beyond desensitization: physiological 
relevance of arrestin­dependent signaling. Pharmacol Rev 2010; 62: 
305­330 [PMID: 20427692 DOI: 10.1124/pr.109.002436]
14 Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol 
Cell Endocrinol 2004; 228: 23­38 [PMID: 15541570 DOI: 10.1016/
j.mce.2003.12.020]
15 Lymperopoulos A, Brill A, McCrink KA. GPCRs of adrenal 
chromaffin cells & amp; catecholamines: The plot thickens. Int 
J Biochem Cell Biol 2016; 77: 213­219 [PMID: 26851510 DOI: 
10.1016/j.biocel.2016.02.003]
16 Jafferjee M, Reyes Valero T, Marrero C, McCrink KA, Brill 
A, Lymperopoulos A. GRK2 Up­Regulation Creates a Positive 
Feedback Loop for Catecholamine Production in Chromaffin 
Cells. Mol Endocrinol 2016; 30: 372­381 [PMID: 26849467 DOI: 
10.1210/me.2015­1305]
17 Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in 
heart failure: fine-tuning cardiac stimulation. Trends Mol Med 2007; 
13: 503­511 [PMID: 17981507 DOI: 10.1016/j.molmed.2007.10.005]
18 Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. 
Adrenal GRK2 upregulation mediates sympathetic overdrive in 
heart failure. Nat Med 2007; 13: 315­323 [PMID: 17322894 DOI: 
10.1038/nm1553]
19 Rengo G, Lymperopoulos A, Zincarelli C, Femminella G, Liccardo 
D, Pagano G, de Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone 
Filardi P, Koch W, Leosco D. Blockade of β-adrenoceptors restores the 
GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production 
axis in heart failure. Br J Pharmacol 2012; 166: 2430­2440 [PMID: 
22519418 DOI: 10.1111/j.1476­5381.2012.01972.x]
20 Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW, Koch 
WJ. Reduction of sympathetic activity via adrenal­targeted GRK2 
gene deletion attenuates heart failure progression and improves 
cardiac function after myocardial infarction. J Biol Chem 2010; 285: 
16378­16386 [PMID: 20351116 DOI: 10.1074/jbc.M109.077859]
21 Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. 
Modulation of adrenal catecholamine secretion by in vivo gene 
transfer and manipulation of G protein­coupled receptor kinase­2 
activity. Mol Ther 2008; 16: 302­307 [PMID: 18223549 DOI: 
10.1038/sj.mt.6300371]
22 Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a 
novel gene therapy target in heart failure. J Mol Cell Cardiol 2011; 
50: 785­792 [PMID: 20800067 DOI: 10.1016/j.yjmcc.2010.08.014]
23 Rengo G, Lymperopoulos A, Koch WJ. Future g protein­coupled 
receptor targets for treatment of heart failure. Curr Treat Options 
Cardiovasc Med 2009; 11: 328­338 [PMID: 19627665 DOI: 10.217
4/138161212799040475]
24 Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous 
system in heart failure: pathophysiology and therapy. Circ Res 
2013; 113: 739­753 [PMID: 23989716 DOI: 10.1161/CIRCRE­
SAHA.113.300308]
25 McCrink KA, Brill A, Lymperopoulos A. Adrenal G protein­
coupled receptor kinase­2 in regulation of sympathetic nervous 
Lymperopoulos A et al . ARBs and β-arrestin-dependent aldosterone suppression
206 March 26, 2017|Volume 9|Issue 3|WJC|www.wjgnet.com
Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese 
essential hypertensive patients despite drug treatment. Am J Hypertens 
2012; 25: 818­826 [PMID: 22552267 DOI: 10.1038/ajh.2012.47]
47 Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone 
breakthrough during therapy with angiotensin­converting enzyme 
inhibitors and angiotensin II receptor blockers in proteinuric patients 
with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 
462­466 [PMID: 17014562 DOI: 10.1111/j.1440­1797.2006.00665.x]
48 Bomback AS, Klemmer PJ. The incidence and implications of 
aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486­492 
[PMID: 17717561 DOI: 10.1038/ncpneph0575]
49 Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, 
Takano K. Aldosterone breakthrough during angiotensin II receptor 
antagonist therapy in stroke­prone spontaneously hypertensive rats. 
Hypertension 2002; 40: 28­33 [PMID: 12105134 DOI: 10.1161/01.
HYP.0000022606.52221.2F]
50 Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsepin NA, 
James D, Wang D, Nelson G, Weierstall U, Sawaya MR, Xu Q, 
Messerschmidt M, Williams GJ, Boutet S, Yefanov OM, White TA, 
Wang C, Ishchenko A, Tirupula KC, Desnoyer R, Coe J, Conrad 
CE, Fromme P, Stevens RC, Katritch V, Karnik SS, Cherezov V. 
Structure of the Angiotensin receptor revealed by serial femtosecond 
crystallography. Cell 2015; 161: 833­844 [PMID: 25913193 DOI: 
10.1016/j.cell.2015.04.011]
51 Balakumar P, Jagadeesh G. Structural determinants for binding, 
activation, and functional selectivity of the angiotensin AT1 
receptor. J Mol Endocrinol 2014; 53: R71­R92 [PMID: 25013233 
DOI: 10.1530/JME­14­0125]
P- Reviewer: Lin GM, Said SAM, Ueda H    S- Editor: Gong XM 
L- Editor: A    E- Editor: Wu HL
40 Dabul S, Bathgate­Siryk A, Valero TR, Jafferjee M, Sturchler E, 
McDonald P, Koch WJ, Lymperopoulos A. Suppression of adrenal 
βarrestin1-dependent aldosterone production by ARBs: head-to-
head comparison. Sci Rep 2015; 5: 8116 [PMID: 25631300 DOI: 
10.1038/srep08116]
41 Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison 
of the properties of clinically used angiotensin II type 1 receptor 
antagonists. Pharmacol Rev 2013; 65: 809­848 [PMID: 23487168 
DOI: 10.1124/pr.112.007278]
42 Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist 
M, Lund LH. Association of candesartan vs losartan with all­cause 
mortality in patients with heart failure. JAMA 2011; 305: 175­182 
[PMID: 21224459 DOI: 10.1001/jama.2010.1949]
43 Svanström H, Pasternak B, Hviid A. Association of treatment 
with losartan vs candesartan and mortality among patients with 
heart failure. JAMA 2012; 307: 1506­1512 [PMID: 22496265 DOI: 
10.1001/jama.2012.452]
44 Shah RV, Desai AS, Givertz MM. The effect of renin­angiotensin 
system inhibitors on mortality and heart failure hospitalization 
in patients with heart failure and preserved ejection fraction: a 
systematic review and meta­analysis. J Card Fail 2010; 16: 260­267 
[PMID: 20206902 DOI: 10.1016/j.cardfail.2009.11.007]
45 Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, 
Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska 
A. Irbesartan in patients with heart failure and preserved ejection 
fraction. N Engl J Med 2008; 359: 2456­2467 [PMID: 19001508 
DOI: 10.1056/NEJMoa0805450]
46 Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessì­
Lymperopoulos A et al . ARBs and β-arrestin-dependent aldosterone suppression
                                      © 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
